Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clearside Biomedical's Total Assets for the quarter that ended in Sep. 2025 was €9.92 Mil.
During the past 12 months, Clearside Biomedical's average Total Assets Growth Rate was -13.10% per year.
During the past 3 years, the average Total Assets Growth Rate was -25.70% per year.
During the past 5 years, the average Total Assets Growth Rate was 6.90% per year.
During the past 10 years, the average Total Assets Growth Rate was 17.20% per year.
During the past 12 years, Clearside Biomedical's highest 3-Year average Total Assets Growth Rate was 73.10%. The lowest was -25.70%. And the median was 35.80%.
Note:
The Net Income data used here is four times the quarterly (Sep. 2025) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Clearside Biomedical's Asset Turnover for the quarter that ended in Sep. 2025 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Clearside Biomedical Total Assets Related Terms
Clearside Biomedical Total Assets Historical Data
* Premium members only.
The historical data trend for Clearside Biomedical's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Clearside Biomedical's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clearside Biomedical (STU:CLM0) has a Total Assets of €9.92 Mil as of Sep. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Clearside Biomedical and its competitors.
Is Clearside Biomedical's Total Assets too high?
Clearside Biomedical's current Total Assets is €9.92 Mil. Overall, Clearside Biomedical has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Clearside Biomedical's Total Assets compare to LYRA and EVFM?
Clearside Biomedical's Total Assets of €9.92 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Clearside Biomedical and its competitors. Clearside Biomedical's current Total Assets is €9.92 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clearside Biomedical stock overvalued right now?
Clearside Biomedical (STU:CLM0) has a current Total Assets of €9.92 Mil. The stock's GF Value™ is €110.06, compared to a current price of €4.35 — trading 96% below its estimated fair value. The current Total Assets is €9.92 Mil. Clearside Biomedical's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Clearside Biomedical (STU:CLM0), the current Total Assets is €9.92 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clearside Biomedical (STU:CLM0) Overvalued in 2026?
Based on GuruFocus' analysis, Clearside Biomedical stock appears to be undervalued.
The current stock price of €4.35 is trading 96% below its estimated GF Value™ of €110.06.
Key valuation signals for STU:CLM0:
Total Assets: €9.92 Mil
GF Value™: €110.06 vs. price of €4.35 (96% below fair value)
No single metric tells the full story. See the STU:CLM0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
49GF Score
Get the complete analysis for STU:CLM0
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:CLM0 has been successfully added to your 
